SCHEMBL5287072

SCHEMBL5287072

COc1ccc2c(c1)CN(c1cnnc3cc(OC)c(OC)cc13)CC2

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.47
PDE10A Q9Y233 3/20 0.46
ADRA1D P25100 1/20 0.44
ADRA1A P35348 1/20 0.44
ADRA1B P35368 1/20 0.44
MAPT P10636 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
KMT2A Q03164 1/20 0.40
DRD1 P21728 1/20 0.40
DRD5 P21918 1/20 0.40
RAB9A P51151 1/20 0.40
TIPARP Q7Z3E1 2/20 0.39
MAOB P27338 1/20 0.39
PKM P14618 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5301608 0.96 PDGFRB (0.47) PDGFRBPDE10AADRA1DADRA1AADRA1B
SCHEMBL5279420 0.90 PDGFRB (0.58) PDGFRBPDE10AADRA1DADRA1AADRA1B
SCHEMBL5243987 0.89 TIPARP (0.43) PDGFRBPDE10AADRA1DADRA1AADRA1B
SCHEMBL5246573 0.89 PDE10A (0.46) PDGFRBPDE10AADRA1DADRA1AADRA1B
SCHEMBL5244659 0.88 ADRA1D (0.55) PDGFRBPDE10AADRA1DADRA1AADRA1B
Hydrochloric Acid SCHEMBL5246264 0.88 TIPARP (0.43) PDGFRBPDE10AADRA1DADRA1AADRA1B
SCHEMBL8267151 0.88 PDGFRB (0.40) PDGFRBPDE10AADRA1DADRA1AADRA1B
SCHEMBL5243560 0.88 RAB9A (0.51) PDGFRBPDE10AADRA1DADRA1AADRA1B
SCHEMBL8266253 0.88 ADRA1D (0.48) PDGFRBPDE10AADRA1DADRA1AADRA1B
SCHEMBL5288680 0.87 PDE10A (0.53) PDGFRBPDE10AADRA1DADRA1AADRA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1802585-A1 4-SUBSTITUTED 4,6-DIALKOXY-CINNOLINE DERIVATIVES AS PHOSPODIESTERASE 10 INHIBITORS FOR THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL SYNDROMS Memory Pharmaceuticals Corporation (US) 2007-07-04 EP claimed
US-20060160814-A1 Phosphodiesterase 10 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2006-07-20 US claimed
WO-2006028957-A1 4-SUBSTITUTED 4, 6-DIALKOXY-CINNOLINE DERIVATIVES AS PHOSPODIESTERASE 10 INHIBITORS FOR THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL SYNDROMS MEMORY PHARMACEUTICALS CORPORATION (US) 2006-03-16 WO claimed
EP-1802585-A1 4-SUBSTITUTED 4,6-DIALKOXY-CINNOLINE DERIVATIVES AS PHOSPODIESTERASE 10 INHIBITORS FOR THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL SYNDROMS Memory Pharmaceuticals Corporation (US) 2007-07-04 EP disclosed
US-20060160814-A1 Phosphodiesterase 10 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2006-07-20 US disclosed
WO-2006028957-A1 4-SUBSTITUTED 4, 6-DIALKOXY-CINNOLINE DERIVATIVES AS PHOSPODIESTERASE 10 INHIBITORS FOR THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL SYNDROMS MEMORY PHARMACEUTICALS CORPORATION (US) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160814-A1 Phosphodiesterase 10 inhibitors PDE5A, PDE3A, PDE2A PDGFRB 992/4885PDE10A 8/4885ADRA1D 143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.